VCNX VCNX

Vaccinex Stock Price

0.74
0.0893 (13.72%)
Upgrade to Real-Time
Afterhours (Closed)
0.74
Volume 236,164
Bid Price 0.72
Ask Price 0.7236
News -
Day High 0.76

Low
0.41

52 Week Range

High
2.28

Day Low 0.66
Company Name Stock Ticker Symbol Market Type
Vaccinex Inc VCNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0893 13.72% 0.74 17:10:06
Open Price Low Price High Price Close Price Prev Close
0.68 0.66 0.76 0.7395 0.6507
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
475 236,164 $ 0.7257378 $ 171,393 - 0.41 - 2.28
Last Trade Time Type Quantity Stock Price Currency
19:26:08 1 $ 0.7236 USD

Period:

Draw Mode:

Vaccinex Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 36.91M 49.88M 30.20M $ 900.00k $ - -0.79 -1.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 5.55M 0.70%

more financials information »

Vaccinex News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VCNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.500.760.4470.5454385113,2200.2448.0%
1 Month0.550.760.410.533623658,0680.1934.55%
3 Months0.730.82660.410.571324368,0030.011.37%
6 Months1.371.500.410.9119739104,094-0.63-45.99%
1 Year1.412.280.411.23400,316-0.67-47.52%
3 Years4.9712.230.413.76811,703-4.23-85.11%
5 Years12.0012.230.413.79571,009-11.26-93.83%

Vaccinex Description

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.